De Novo Lesions and In-Stent Restenosis
| Randomized Controlled Trials | ||||||
|---|---|---|---|---|---|---|
| Year | Name | Primary Investigator | Study Aim | (Primary) Endpoint | Patients | Further Information |
| 2020 | BASKET-SMALL 2 | Jeger R | SQP vs. DES Vessel: RD ≤ 3 mm | MACE @ 36-month follow-up | 758 | Pubmed |
| 2017 | PEPCAD Japan SVD | Funatsu A | DCB vs. POBA Vessel: RD ≤ 2.75 mm, ≥ 2 mm | TVF @ 6-month follow-up | 135 | Pubmed |
| 2017 | AMI Feasibility Study | Gobić D | DCB vs. DES Patients: STEMI (< 12 h) | MACE, LLL @ 6-month follow-up | 75 | Pubmed |
| 2016 | Clinical Value "Stent-less" PCI | Nishiyama N | DCB vs. DES | TLR @ 8-month follow-up | 60 | Pubmed |
| Not Randomized Controlled Trials & Observational Studies | ||||||
| Year | Name | Primary Investigator | Study Aim | (Primary) Endpoint | Patients | Further Information |
| 2019 | DCB-only All-Comers Registry | Rosenberg M | DCB – ISR & De Novo | TLR @ 9-month follow-up | 1,025 | Pubmed |
| 2016 | FFR-Guided DCB-Angioplasty | Shin E | DCB – De Novo Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | LLL, FFR @ 9-month follow-up MI, TLR @ 12-month follow-up | 67 | Pubmed |
| 2014 | SVD Registry | Zeymer U | DCB – De Novo Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | TLR @ 9-month follow-up | 447 | Pubmed |